Summit Therapeutics (SMMT) Treasury Shares (2020 - 2026)

Summit Therapeutics (SMMT) posted quarterly Treasury Shares of $730000.0 for Q2 2026, little changed on a QoQ basis from $730000.0 in Q1 2026.

Summit Therapeutics (SMMT) Treasury Shares (2020 - 2026) Analysis & Trends

Summit Therapeutics (SMMT) has reported Treasury Shares for 2 consecutive years, with $730000.0 the latest figure, recorded in Q2 2026.

Quarterly Treasury Shares changed N/A year-over-year to $730000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $730000.0 (changed N/A YoY) and the FY2020 annual result came in at $26923.0, changed N/A from the prior year.
Treasury Shares was little changed at $730000.0 in Q2 2026 per SMMT's latest filing, from $730000.0 in the prior quarter.
Over the last five years, Treasury Shares for SMMT reached as high as $730000.0 in Q1 2026 and fell as low as $730000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-21,709.08
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	265,401.92
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	19.41 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	5.14 Mn
10	Summit Therapeutics	11.62 Bn	11.03 Bn	-	730,000.00

Download Data